
Wybierz swoją etykietę
widoczna od razu na fiolceEmpagliflozin (Jardiance)
Medication
- Wysyłka z Niemiec
Zamówienie
- DHL ze śledzeniem
- Dyskretne opakowanie
W skrócie
Empagliflozin (Jardiance) w liczbach
Najważniejsze dane z naszego leksykonu. Przeciągnij punkt wzdłuż krzywej, aby zobaczyć, ile zostaje po jednej dawce, według obliczeń.
Pełny wpis w leksykonieHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~12 hours
Simplified model without an absorption phase, half-life from the TPD lexicon.
Half-life
about12hours
effect lasts 24h
- Class
- SGLT2 inhibitorselective, oral
- Use
- Oralonce daily in the morning
- Sizes
- 10 to 25 mg2 sizes in the shop
What studies show
All 5 sources in the lexicon- Zinman et al., NEJM, 2015
- Packer et al., NEJM, 2020
- Anker et al., NEJM, 2021
Opinie
Co mówią klienci
Tylko prawdziwe zamówienia, które zawierały Empagliflozin (Jardiance).
Wszystkie opinieDla Empagliflozin (Jardiance) nie ma jeszcze analizy laboratoryjnej. ZagłosujZleć test samodzielnie, zapłacimy połowęWszystkie analizy laboratoryjne
Wiedza
Wszystko o Empagliflozin (Jardiance)
Szczegółowe informacje wkrótce.
Is empagliflozin approved?
Yes. In the USA it has been marketed as a prescription drug since 1 August 2014. According to the label for type 2 diabetes, to reduce cardiovascular death in diabetes with cardiovascular disease and in heart failure. It is not recommended in type 1 diabetes because of the ketoacidosis risk.
How does empagliflozin work?
It blocks SGLT2 in the kidney, the transporter that takes sugar back from the urine. In a cell assay a concentration of 3.1 nM was enough for half-maximal inhibition. Of all inhibitors tested it was the most selective over the gut transporter SGLT1. The sugar is lost with the urine, independently of insulin.
What did EMPA-REG OUTCOME show?
7,020 people with type 2 diabetes and cardiovascular disease were followed for a median of 3.1 years. The primary outcome of cardiovascular death, heart attack and stroke fell from 12.1 to 10.5 percent. Cardiovascular deaths fell by 38 percent, hospitalisations for heart failure by 35 percent and deaths from any cause by 32 percent. Heart attack and stroke did not differ significantly.
Does it also work without diabetes?
In heart failure, yes. In EMPEROR-Reduced and EMPEROR-Preserved the effect was the same with and without diabetes, likewise in chronic kidney disease in EMPA-KIDNEY. With reduced ejection fraction kidney function fell by 0.55 instead of 2.28 ml per minute per year.
What is euglycaemic ketoacidosis?
Acidification of the blood by ketone bodies while blood sugar is normal or only slightly raised. On SGLT2 inhibitors the typical warning sign of high sugar is therefore missing. The medical literature describes it as a predictable, detectable and preventable risk of the drug class.
Which side effects have been described?
In EMPA-REG OUTCOME only genital infections were more common than on placebo. In EMPEROR-Reduced uncomplicated genital infections were more common, in EMPEROR-Preserved also urinary tract infections and low blood pressure. In EMPA-KIDNEY serious adverse events were equally common in both groups.
Powiązane
Podobne produkty
Telmisartan
Leki · Układ sercowo-naczyniowy Układ sercowo-naczyniowy
2 rozmiary
Testowane w laboratorium
Ivermectin
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Fenbendazol
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Prednisone
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Empagliflozin (Jardiance)